Patent intelligence · US
US 9102698
Process for the synthesis of IB-MECA
Process for the synthesis of IB-MECA
Patent details — US 9102698
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 11, 2015
- Expiration
- Aug 6, 2035
- Applicant
- CAN-FITE BIOPHARMA LTD.
- Claims
- 13
- CPC classes
- A61P, A61P19/02, A61P19/10, A61P27/02
Quick answer
US 9102698 (Process for the synthesis of IB-MECA) is held by CAN-FITE BIOPHARMA LTD.. Status: granted. Granted Aug 11, 2015. Expires Aug 6, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CAN-FITE BIOPHARMA LTD.
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61P, A61P19/02, A61P19/10, A61P27/02, A61P29/00, A61P31/12
More from CAN-FITE BIOPHARMA LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12213990
A3 adenosine receptor ligand for use for achieving a fat loss effect
granted -
US 11291681
Method for treating fibrotic liver tissue using Cl-IB-MECA
granted -
US 10780106
Method for treating NASH accompanied by fibrosis using Cl-IB-MECA
granted -
US 10265337
Use of A3 adenosine receptor agonist in osteoarthritis treatment
granted -
US 9549943
A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
granted -
US 9387220
Method for inducing hepatocyte proliferation and uses thereof
granted -
US 8987228
Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(IB-MECA/CF-101) for treatment of psoriasis
granted
Related coverage
Frequently asked questions
What is US patent 9102698?
US 9102698 (Process for the synthesis of IB-MECA) is held by CAN-FITE BIOPHARMA LTD.. Status: granted. Granted Aug 11, 2015. Expires Aug 6, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9102698?
CAN-FITE BIOPHARMA LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.
When does US 9102698 expire?
Our index shows an expiration date of Aug 6, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.